No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients

Madlyne Becker, Clotilde Latarche, Emilie Roman, Marc Debouverie, Catherine Malaplate-Armand, Francis Guillemin, Madlyne Becker, Clotilde Latarche, Emilie Roman, Marc Debouverie, Catherine Malaplate-Armand, Francis Guillemin

Abstract

Background: We aimed to determine the association of clinical and routine cerebrospinal fluid biochemical markers (total protein, IgG index and oligoclonal bands) with disability in multiple sclerosis and whether these biomarkers assessed at diagnosis add prognostic value.

Methods: We followed a cohort of patients included in the Multiple Sclerosis Lorraine Register (eastern France) who had a diagnosis of multiple sclerosis for at least 5 years, as well as biological markers values and MRI findings (Barkhof's criteria). In a Cox regression model, endpoint was time to score of 4 on the Expanded Disability Status Scale (EDSS) (i.e., limited time walking without aid or rest for more than 500 m).

Results: For 407 patients included, the median time from multiple sclerosis onset to EDSS score 4 was 4.5 years [2.2-7.2]. Cerebrospinal fluid total protein factor < 500 mg/L was associated with EDSS score 4 on bivariate analysis (hazard ratio 0.66, 95% confidence interval 0.46-0.95, p = 0.02). On multivariate analysis, older age at disease onset (≥50 years) and initial primary progressive course of MS but not biological markers predicted worse prognosis.

Conclusion: Routine cerebrospinal fluid biological markers at diagnosis were not prognostic factors of multiple sclerosis progression.

Figures

Figure 1
Figure 1
Flow chart of patient selection according to inclusion criteria.

References

    1. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62(6):865–70.
    1. Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S, et al. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol. 2006;13(9):913–22. doi: 10.1111/j.1468-1331.2006.01493.x.
    1. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol. 2006;180(1-2):17–28. doi: 10.1016/j.jneuroim.2006.07.006.
    1. Villar LM, Masterman T, Casanova B, Gomez-Rial J, Espino M, Sadaba MC, et al. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J Neuroimmunol. 2009;211(1-2):101–4. doi: 10.1016/j.jneuroim.2009.03.003.
    1. Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol. 2010;219(1-2):1–7. doi: 10.1016/j.jneuroim.2009.09.002.
    1. Izquierdo G, Angulo S, Garcia-Moreno JM, Gamero MA, Navarro G, Gata JM, et al. Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients. Acta Neurol Scand. 2002;105(3):158–63. doi: 10.1034/j.1600-0404.2002.1o009.x.
    1. Olsson JE, Link H, Muller R. Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: disability, duration and age of onset. J Neurol Sci. 1976;27(2):233–45. doi: 10.1016/0022-510X(76)90064-2.
    1. Stendahl-Brodin L, Link H. Relation between benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid. J Neurol Neurosurg Psychiatry. 1980;43(2):102–5. doi: 10.1136/jnnp.43.2.102.
    1. Avasarala JR, Cross AH, Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol. 2001;58(12):2044–5. doi: 10.1001/archneur.58.12.2044.
    1. Joseph FG, Hirst CL, Pickersgill TP, Ben Shlomo Y, Robertson NP, Scolding NJ. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry. 2009;80(3):292–6. doi: 10.1136/jnnp.2008.150896.
    1. Rojas JI, Patrucco L, Cristiano E. Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis. J Neurol. 2010;257(7):1188–91. doi: 10.1007/s00415-010-5561-0.
    1. Verjans E, Theys P, Delmotte P, Carton H. Clinical parameters and intrathecal IgG synthesis as prognostic features in multiple sclerosis. Part I J Neurol. 1983;229(3):155–65. doi: 10.1007/BF00313739.
    1. Idiman E, Ozakbas S, Dogan Y, Kosehasanogullari G. The significance of oligoclonal bands in multiple sclerosis: relevance of demographic and clinical features, and immunogenetic backgrounds. J Neuroimmunol. 2009;212(1-2):121–4. doi: 10.1016/j.jneuroim.2009.04.014.
    1. Siritho S, Freedman MS. The prognostic significiance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci. 2009;15(279(1-2):21–5. doi: 10.1016/j.jns.2008.12.029.
    1. Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis. 2009;35(2):117–27. doi: 10.1016/j.nbd.2009.04.010.
    1. Annunziata P, Giorgio A, De Santi L, Zipoli V, Portaccio E, Amato MP, et al. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. J Neurol Sci. 2006;244(1-2):97–102. doi: 10.1016/j.jns.2006.01.004.
    1. Zeman AZJ, Kidd D, McLean BN, Kelly MA, Francis DA, Miller DH, et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;60:27–30. doi: 10.1136/jnnp.60.1.27.
    1. Mayringer I, Timeltaler B, Deisenhammer F. Correlation between the IgG index, oligoclonal bands in CSF, and the diagnosis of demyelinating diseases. Eur J Neurol. 2005;12(7):527–30. doi: 10.1111/j.1468-1331.2005.00997.x.
    1. Imrell K, Greiner E, Hillert J, Masterman T. HLA-DRB115 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J Neuroimmunol. 2009;210(1-2):128–30. doi: 10.1016/j.jneuroim.2009.03.005.
    1. Rojas JI, Tizio S, Patrucco L, Cristiano E. Oligoclonal bands in multiple sclerosis patients: worse prognosis? Neurol Res. 2012;34(9):889–92. doi: 10.1179/1743132812Y.0000000088.
    1. Gajofatto A, Bongianni M, Zanusso G, Benedetti MD, Monaco S. Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? Int J Mol Sci. 2011;12(11):7960–70. doi: 10.3390/ijms12117960.
    1. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430–8. doi: 10.1056/NEJM200011163432001.
    1. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008;15(9):916–21. doi: 10.1111/j.1468-1331.2008.02241.x.
    1. Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158–64. doi: 10.1056/NEJMoa011341.
    1. Leibowitz U, Alter M. Clinical factors determining prognosis in multiple sclerosis. Neurology. 1968;18(3):286–7. doi: 10.1212/WNL.18.3.286.
    1. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980;103(2):281–300. doi: 10.1093/brain/103.2.281.
    1. Detels R, Clark VA, Valdiviezo NL, Visscher BR, Malmgren RM, Dudley JP. Factors associated with a rapid course of multiple sclerosis. Arch Neurol. 1982;39(6):337–41. doi: 10.1001/archneur.1982.00510180015003.
    1. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology. 2011;77(13):1246–52. doi: 10.1212/WNL.0b013e318230a17d.
    1. Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol. 2007;20(3):269–74. doi: 10.1097/WCO.0b013e32812583ad.
    1. Debouverie M, Pittion-Vouyovitch S, Louis S, Roederer T, Guillemin F. Increasing incidence of multiple sclerosis among women in Lorraine. Eastern France Mult Scler. 2007;13(8):962–7. doi: 10.1177/1352458507077938.
    1. Debouverie M, Lebrun C, Jeannin S, Pittion-Vouyovitch S, Roederer T, Vespignani H. More severe disability of North Africans vs Europeans with multiple sclerosis in France. Neurology. 2007;68(1):29–32. doi: 10.1212/01.wnl.0000250347.51674.d7.
    1. El Adssi H, Debouverie M, Guillemin F. Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture-recapture method. Mult Scler. 2012;18(9):1244–50. doi: 10.1177/1352458512437811.
    1. Cortese I, Capone S, Luchetti S, Grimaldi LM, Nicosia A, Cortese R. CSF-enriched antibodies do not share specificities among MS patients. Mult Scler. 1998;4(3):118–23. doi: 10.1177/135245859800400305.
    1. Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler. 1998;4(3):111–7. doi: 10.1177/135245859800400304.
    1. Walsh MJ, Tourtellotte WW. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med. 1986;163:41–53. doi: 10.1084/jem.163.1.41.
    1. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1992;55:671–6. doi: 10.1136/jnnp.55.8.671.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33(11):1444–52. doi: 10.1212/WNL.33.11.1444.
    1. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(Pt 11):2059–69. doi: 10.1093/brain/120.11.2059.
    1. Hosmer DW, Lemeshow S, May S. Applied Survival Analysis. 2. Hoboken: John Wiley & Sons; 2008.
    1. Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber WE, Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler. 2012;0(0):1–8.
    1. Debouverie M. Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine. France J Neurol Sci. 2009;286(1-2):14–7. doi: 10.1016/j.jns.2009.07.012.
    1. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci. 2003;206(2):135–7. doi: 10.1016/S0022-510X(02)00426-4.
    1. Abraira V, Alvarez-Cermeno JC, Arroyo R, Camara C, Casanova B, Cubillo S, et al. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. J Immunol Methods. 2011;371(1-2):170–3. doi: 10.1016/j.jim.2011.06.009.
    1. Hintzen RQ, Giovannoni G. CSF analysis in suspected MS: do bands aid? Neurology. 2008;70:1059–60. doi: 10.1212/01.wnl.0000306413.29367.82.
    1. Cepok S, Jacobsen M, Schock S, Omer B, Jaekel S, Boddeker I, et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain. 2001;124(Pt 11):2169–76. doi: 10.1093/brain/124.11.2169.
    1. Binquet C, Quantin C, Le TG, Pagliano JF, Abrahamowicz M, Moreau T. The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis. Neuroepidemiology. 2006;27(1):45–54. doi: 10.1159/000094380.
    1. Hecker M, Paap BK, Goertsches RH, Kandulski O, Fatum C, Koczan D, et al. Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PLoS One. 2011;6(12) doi: 10.1371/journal.pone.0029648.
    1. Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol. 2008;255(7):1023–31. doi: 10.1007/s00415-008-0827-5.
    1. Calabrese M, Federle L, Bernardi V, Rinaldi F, Favaretto A, Varagnolo MC, et al. The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Mult Scler. 2012;18(2):174–80. doi: 10.1177/1352458511418550.
    1. Bejarano B, Bianco M, Gonzalez-Moron D, Sepulcre J, Goni J, Arcocha J, et al. Computational classifiers for predicting the short-term course of Multiple sclerosis. BMC Neurol. 2011;11:67. doi: 10.1186/1471-2377-11-67.
    1. Huttner HB, Schellinger PD, Struffert T, Richter G, Engelhorn T, Bassemir T, et al. MRI criteria in MS patients with negative and positive oligoclonal bands: equal fulfillment of Barkhof’s criteria but different lesion patterns. J Neurol. 2009;256(7):1121–5. doi: 10.1007/s00415-009-5081-y.
    1. Andreadou E, Chatzipanagiotou S, Constantinides VC, Rombos A, Stamboulis E, Nicolaou C. Prevalence of cerebrospinal fluid oligoclonal IgG bands in Greek patients with clinically isolated syndrome and multiple sclerosis. Clin Neurol Neurosurg. 2013;115:2094–8. doi: 10.1016/j.clineuro.2013.07.026.
    1. Debouverie M, Laforest L, Van Ganse E, Guillemin F, LORSEP Group Earlier disability of the patients followed in multiple Sclerosis centers compared to outpatients. Mult Scler. 2009;15(2):251–7. doi: 10.1177/1352458508097919.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel